CDMO

In a report released on September 6, Sean Dodge from RBC Capital maintained a Buy rating on Avid Bioservices (CDMO - Research Report), with a price target of $22.00. The company's shares closed yesterday at $16.24.According to TipRanks, Dodge is an analyst with an average return of -2.8% and a 44.11% success rate. Dodge covers the Technology sector, focusing on stocks such as Signify Health, GoodRx Holdings, and Thorne HealthTech.Avid Bioservices has an analyst consensus of Moderate Buy, with a price target consensus of $22.00.
https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-avid-bioservices-cdmo?utm_source=advfn.com&utm_medium=referral